<?xml version="1.0" encoding="UTF-8"?>
<p>Antibody therapy is considered an effective and powerful treatment strategy against many infectious pathogens. While studies of whole-blood transfusion or serum as passive immunity for EBOV treatment have demonstrated limited efficacy, monoclonal antibodies have shown promise in animal models and have been tested in human clinical trials [
 <xref rid="pntd.0006530.ref011" ref-type="bibr">11</xref>–
 <xref rid="pntd.0006530.ref015" ref-type="bibr">15</xref>]. The most successful of these is the antibody cocktail ZMapp, which comprises three humanized murine monoclonal antibodies that target the EBOV GP. ZMapp reversed advanced disease and rescued 100% of rhesus macaques up to 5 days post-viral challenge; however, it did not meet a pre-specified threshold for efficacy in humans when tested during the 2013–2016 outbreak [
 <xref rid="pntd.0006530.ref013" ref-type="bibr">13</xref>, 
 <xref rid="pntd.0006530.ref016" ref-type="bibr">16</xref>].
</p>
